Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345242 | 1.00 | ALOX5 (0.47) | ALOX5PRKCAPRKCDPARP10KCNH2 | |
| SCHEMBL6246290 | 0.85 | SLC6A3 (0.38) | — | |
| SCHEMBL464738 | 0.80 | ACACB (0.44) | ALOX5PRKCAPRKCDFFAR1MAOB | |
| SCHEMBL13117273 | 0.72 | LMNA (0.51) | ALOX5MAOB | |
| SCHEMBL4435910 | 0.69 | ALOX5 (0.58) | ALOX5PARP10FFAR1MAOB | |
| SCHEMBL13617902 | 0.69 | BCL2 (0.53) | LTA4H | |
| SCHEMBL3291046 | 0.69 | BCL2 (0.53) | LTA4H | |
| SCHEMBL471109 | 0.69 | BCL2 (0.53) | LTA4H | |
| SCHEMBL6158180 | 0.69 | BCL2 (0.53) | LTA4H | |
| SCHEMBL8230963 | 0.69 | BCL2 (0.53) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069303-B1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2069303-A2 | ANTIVIRAL PROTEASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| WO-2008011117-A2 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | ALOX5 3112/4885PRKCA 2456/4885PRKCD 3459/4885 |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | ALOX5 2984/4885PRKCA 2165/4885PRKCD 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.